Investors Buy Shares of Alexion Pharmaceuticals (ALXN) on Weakness

Traders purchased shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on weakness during trading hours on Thursday. $74.05 million flowed into the stock on the tick-up and $60.37 million flowed out of the stock on the tick-down, for a money net flow of $13.68 million into the stock. Of all equities tracked, Alexion Pharmaceuticals had the 33rd highest net in-flow for the day. Alexion Pharmaceuticals traded down ($2.64) for the day and closed at $106.78

A number of research analysts recently commented on the company. Leerink Swann reissued a “buy” rating and issued a $182.00 price target on shares of Alexion Pharmaceuticals in a report on Monday, September 25th. Zacks Investment Research cut Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. Royal Bank Of Canada assumed coverage on Alexion Pharmaceuticals in a report on Thursday, September 14th. They issued an “outperform” rating and a $161.00 price target on the stock. BMO Capital Markets reissued an “outperform” rating and issued a $173.00 price target (up from $168.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. Finally, Evercore ISI assumed coverage on Alexion Pharmaceuticals in a report on Wednesday, August 16th. They issued an “in-line” rating and a $137.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $154.49.

The company has a market cap of $23,930.00, a PE ratio of 22.27, a price-to-earnings-growth ratio of 1.18 and a beta of 1.18. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.51 and a current ratio of 2.96.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.12. The firm had revenue of $859.00 million for the quarter, compared to the consensus estimate of $864.34 million. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS. equities research analysts forecast that Alexion Pharmaceuticals, Inc. will post 4.82 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in shares of Alexion Pharmaceuticals by 7.0% during the 2nd quarter. BlackRock Inc. now owns 19,926,265 shares of the biopharmaceutical company’s stock valued at $2,424,428,000 after purchasing an additional 1,298,185 shares during the last quarter. Vanguard Group Inc. grew its position in Alexion Pharmaceuticals by 2.2% in the 2nd quarter. Vanguard Group Inc. now owns 14,785,831 shares of the biopharmaceutical company’s stock valued at $1,798,992,000 after acquiring an additional 318,375 shares during the last quarter. State Street Corp grew its position in Alexion Pharmaceuticals by 5.0% in the 2nd quarter. State Street Corp now owns 11,860,647 shares of the biopharmaceutical company’s stock valued at $1,443,099,000 after acquiring an additional 561,962 shares during the last quarter. Ameriprise Financial Inc. grew its position in Alexion Pharmaceuticals by 3.5% in the 3rd quarter. Ameriprise Financial Inc. now owns 6,390,301 shares of the biopharmaceutical company’s stock valued at $896,491,000 after acquiring an additional 215,005 shares during the last quarter. Finally, Jennison Associates LLC grew its position in Alexion Pharmaceuticals by 720.0% in the 3rd quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock valued at $748,116,000 after acquiring an additional 4,682,336 shares during the last quarter. 94.16% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This story was reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://www.thelincolnianonline.com/2017/12/07/investors-buy-shares-of-alexion-pharmaceuticals-alxn-on-weakness.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply